Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases

Breast Cancer Clinical Trial

Official title:

A Phase Ib/II Pilot Study of Pyrotinib Plus Capecitabine Combined With Brain Radiotherapy in HER2 Positive Breast Cancer Patients With Brain Metastases

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04582968
• Other study ID #: FDRT-BC010
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: January 2, 2020
• Est. completion date: August 12, 2023

Study information

• Verified date: January 2023
• Source: Fudan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Brain metastases occur in 30-50% of patients with metastatic HER2-positive breast cancer. Pyrotinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) with activity against epidermal growth factor receptor (EGFR)/HER1, HER2, and HER4. This study consists of two parts. In a phase Ib part, investigators will explore the safety and tolerance of Pyrotinib Plus Capecitabine combined with brain radiotherapy. After completing the phase Ib part, investigators will review the data and decide whether this patient is included in before the start of a phase II part. In the phase II part, investigators will evaluate the efficacy of Pyrotinib Plus Capecitabine combined with brain radiotherapy in patients with HER2 positive breast cancer patients with brain metastases.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 39
• Est. completion date: August 12, 2023
• Est. primary completion date: August 12, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Pathologically confirmed HER2 positive advanced breast cancer

2. Age>18 years. brain metastases confirmed by enhanced brain MRI

3. KPS=70

4. Life expectancy of more than 12 weeks

5. Prior therapy of oral dexamethasone not exceeding 16mg/d

6. Time interval from prior therapy was more than 2 weeks, and evaluation of adverse events is no more than grade 1.

7. Maximum diameter of intracranial metastases is less than 3cm measured by enhanced brain MRI(2-3mm)

8. Prior endocrine therapy were allowed

9. Anti-Her2 targeted treatment were allowed

10. Screening laboratory values must meet the following criteria( and should be obtained within 28 days prior to registration):

1. Absolute Neutrophil Count (ANC) = 1.5 x 109/L, Platelets= 90 x 109/L, Hemoglobin = 90 g/L

2. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) =2.5 x ULN without liver metastasis,= 5 x ULN with liver metastases

3. Serum BUN and creatinine = 1.5 x Upper Limit of Normal (ULN)

4. LVEF = 50%

5. QTcF < 480 ms

6. INR=1.5×ULN,APTT=1.5×ULN

11. Signed the informed consent form prior to patient entry

Exclusion Criteria:

1. Leptomeningeal or hemorrhagic metastases

2. uncontrolled epilepsy

3. Severe complication: cardiovascular disease, end-stage renal disease, severe hepatic disease, infection etc.

4. Pregnancy or lactation period, women of child-bearing age who are unwilling to accept contraceptive measures.

5. Inability to complete enhanced MRI

6. Patients who are difficult or unable to be followed-up

7. Not suitable for inclusion for specific reasons judged by sponsor

8. Patients unable to swallow, with chronic diarrhea, intestinal obstruction, or multiple factors that affect drug use and absorption

9. History of allergy to pyrotinib or capetabine

10. History of immunodeficiency, including HIV positive, active HBV/HCV or other acquired, congenital immunodeficiency disease, or organ transplantation history

11. Previous use of pyrotinib combined with capetabine

Related Conditions & MeSH terms

• Brain Metastases
• Brain Neoplasms
• Breast Cancer
• Breast Neoplasms
• HER2-positive Breast Cancer
• Neoplasm Metastasis

Intervention

Other:
• Pyrotinib Plus Capecitabine combined with brain radiotherapy
Drug combined with radiation

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess safety and tolerability of Pyrotinib Plus Capecitabine combined with brain radiotherapy(Phase Ib part)	AEs will be assessed according to CTCAE version 4.03.; (1)Initially 3 patients will be accrued and treated with combined therapy as a lead-in safety phase. Enrollment of the study will not proceed if patients in the safety lead-in phase experience unacceptable toxicities including neurologic, hematologic and other dose limiting toxicities.(see protocol) (b)If one of initially 3 patients has experienced unacceptable toxicities, 3 more patients will be accrued .; (3)If two or more patients are unable to complete radiation therapy (RT) due to toxicity related to Pyrotinib Plus Capecitabine combined with brain radiotherapy, accrual will be suspended and the study will be stopped.; (4) If 3+3 patients are able to complete the treatment without unacceptable toxicities, 6 more patients will be accrued in Ib part.	8 weeks
Primary	Intracranial local tumor control rate (Phase II part)	All intracranial progression	2 years
Secondary	Intracranial local tumor control rate with FSRT or WBRT	Intracranial local tumor control rate	2 years
Secondary	Intracranial Progression-Free Survival (PFS)	Time from the date of radiotherapy to the investigator-determined date of progression (determined by RANO) or death due to any cause, whichever occurs first	2 years
Secondary	Extracranial Progression-Free Survival (PFS)		2 years
Secondary	OS (overall survival)		3 years